ImmunityBio (IBRX) Accumulated Expenses (2014 - 2026)

ImmunityBio (IBRX) has reported Accumulated Expenses for 13 consecutive years, with $48.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 72.84% year-over-year to $48.2 million; the TTM figure through Mar 2026 stood at $48.2 million (up 72.84% YoY), while the FY2025 annual figure was $46.8 million, up 15.42% from the prior year.
• Accumulated Expenses rose to $48.2 million in Q1 2026 per IBRX's latest filing, from $46.8 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $64.9 million in Q3 2023 and bottomed at $44000.0 in Q2 2024.
• Historically, Accumulated Expenses has averaged $41.4 million across 5 years, with a median of $43.6 million in 2025.
• Annual changes were most pronounced in 2024 — Accumulated Expenses sank 99.93% — and 2025, when it jumped 81047.73%.
• ImmunityBio's Accumulated Expenses stood at $41.8 million in 2022, then rose by 2.11% to $42.7 million in 2023, then decreased by 4.98% to $40.6 million in 2024, then increased by 15.42% to $46.8 million in 2025, then grew by 2.92% to $48.2 million in 2026.
• Business Quant data shows IBRX's Accumulated Expenses at $48.2 million in Q1 2026, $46.8 million in Q4 2025, and $43.6 million in Q3 2025.